Lixte Biotechnology Holdings Stock Performance

LIXT Stock  USD 3.12  0.06  1.96%   
The company secures a Beta (Market Risk) of 0.36, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lixte Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Lixte Biotechnology is expected to be smaller as well. At this point, Lixte Biotechnology has a negative expected return of -0.39%. Please make sure to verify Lixte Biotechnology's potential upside and day median price , to decide if Lixte Biotechnology performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Lixte Biotechnology Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more

Actual Historical Performance (%)

One Day Return
1.96
Five Day Return
2.3
Year To Date Return
(18.75)
Ten Year Return
(82.07)
All Time Return
(99.88)
Last Split Factor
1:10
Dividend Date
2020-11-20
Last Split Date
2023-06-05
1
LIXTE Biotechnology Acquires Liora Technologies Proprietary Proton Therapy Platform for Cancer Treatment
11/25/2025
2
LIXTEs Strategy Comes Into Focus Building an Oncology Platform Around Complementary Modalities
12/08/2025
3
Lixte Biotechnology Holdings, Inc. Announces 4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
12/18/2025
4
Will Lixte Biotechnology Holdings Inc. stock see insider buying - Take Profit Strategies Trusted Financial Advisors at No Cost - Bollywood Helpline
12/23/2025
5
Acquisition by Felix Lourdes of 25000 shares of Lixte Biotechnology at 4.05 subject to Rule 16b-3
12/24/2025
6
Acquisition by Yen Yun of 100000 shares of Lixte Biotechnology subject to Rule 16b-3
12/29/2025
7
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.
01/13/2026
8
DE LA SOUL-LED GOOD HEALTH SUMMIT LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
01/21/2026
9
Acquisition by Primus Guy Warren of 25000 shares of Lixte Biotechnology at 4.05 subject to Rule 16b-3
01/30/2026
10
Lixte Biotechnology Holdings, Inc. Short Interest Down 14.0 percent in January
02/05/2026
11
LIXTE Biotechnology Bringing First-in-Class Approach to Chemo and Immunotherapy
02/12/2026

Lixte Biotechnology Relative Risk vs. Return Landscape

If you would invest  421.00  in Lixte Biotechnology Holdings on November 15, 2025 and sell it today you would lose (109.00) from holding Lixte Biotechnology Holdings or give up 25.89% of portfolio value over 90 days. Lixte Biotechnology Holdings is currently does not generate positive expected returns and assumes 4.7856% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Lixte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Lixte Biotechnology is expected to under-perform the market. In addition to that, the company is 6.16 times more volatile than its market benchmark. It trades about -0.08 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of volatility.

Lixte Biotechnology Target Price Odds to finish over Current Price

The tendency of Lixte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 3.12 90 days 3.12 
under 95
Based on a normal probability distribution, the odds of Lixte Biotechnology to move above the current price in 90 days from now is under 95 (This Lixte Biotechnology Holdings probability density function shows the probability of Lixte Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Lixte Biotechnology has a beta of 0.36. This indicates as returns on the market go up, Lixte Biotechnology average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Lixte Biotechnology Holdings will be expected to be much smaller as well. Additionally Lixte Biotechnology Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Lixte Biotechnology Price Density   
       Price  

Predictive Modules for Lixte Biotechnology

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lixte Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lixte Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.153.077.82
Details
Intrinsic
Valuation
LowRealHigh
0.142.817.56
Details

Lixte Biotechnology Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Lixte Biotechnology is not an exception. The market had few large corrections towards the Lixte Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lixte Biotechnology Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lixte Biotechnology within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.39
β
Beta against Dow Jones0.36
σ
Overall volatility
0.46
Ir
Information ratio -0.09

Lixte Biotechnology Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lixte Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lixte Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Lixte Biotechnology generated a negative expected return over the last 90 days
Lixte Biotechnology has high historical volatility and very poor performance
Lixte Biotechnology has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (3.59 M) with profit before overhead, payroll, taxes, and interest of 0.
Lixte Biotechnology Holdings currently holds about 7.74 M in cash with (3.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Lixte Biotechnology has a frail financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: LIXTE Biotechnology Bringing First-in-Class Approach to Chemo and Immunotherapy

Lixte Biotechnology Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lixte Stock often depends not only on the future outlook of the current and potential Lixte Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lixte Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding2.2 M
Cash And Short Term InvestmentsM

Lixte Biotechnology Fundamentals Growth

Lixte Stock prices reflect investors' perceptions of the future prospects and financial health of Lixte Biotechnology, and Lixte Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lixte Stock performance.

About Lixte Biotechnology Performance

Assessing Lixte Biotechnology's fundamental ratios provides investors with valuable insights into Lixte Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Lixte Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(2.82)(2.96)
Return On Capital Employed(4.97)(5.22)
Return On Assets(2.82)(2.96)
Return On Equity(4.99)(5.23)

Things to note about Lixte Biotechnology performance evaluation

Checking the ongoing alerts about Lixte Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lixte Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Lixte Biotechnology generated a negative expected return over the last 90 days
Lixte Biotechnology has high historical volatility and very poor performance
Lixte Biotechnology has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (3.59 M) with profit before overhead, payroll, taxes, and interest of 0.
Lixte Biotechnology Holdings currently holds about 7.74 M in cash with (3.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Lixte Biotechnology has a frail financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: LIXTE Biotechnology Bringing First-in-Class Approach to Chemo and Immunotherapy
Evaluating Lixte Biotechnology's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Lixte Biotechnology's stock performance include:
  • Analyzing Lixte Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lixte Biotechnology's stock is overvalued or undervalued compared to its peers.
  • Examining Lixte Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Lixte Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lixte Biotechnology's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Lixte Biotechnology's stock. These opinions can provide insight into Lixte Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Lixte Biotechnology's stock performance is not an exact science, and many factors can impact Lixte Biotechnology's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.